Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: Encouraging results for intermediate- and high-risk prostate cancer

Shea W. Wilcox, Noel J. Aherne, Linus C. Benjamin, Bosco Wu, Thomaz de Campos Silva, Craig S. McLachlan, Michael J. McKay, Andrew J. Last, Thomas P. Shakespeare

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Methods and materials: Patients with localized prostate cancer were identified from a centralized database across an integrated cancer center. All patients received DE IG-IMRT, combined with ADT, and had a minimum follow up of 12 months post-radiotherapy. All relapse and toxicity data were collected prospectively. Actuarial bDFS, metastasis-free survival, prostate cancer-specific survival, and multivariate analyses were calculated using the SPSS v20.0 statistical package.

Results: Seven hundred and eighty-two eligible patients were identified with a median follow up of 46 months. Overall, 4.3% of patients relapsed, 2.0% developed distant metastases, and 0.6% died from metastatic prostate cancer. At 5-years, bDFS was 88%, metastasis-free survival was 95%, and prostate cancer-specific survival was 98%. Five-year grade 2 genitourinary and gastrointestinal toxicity was 2.1% and 3.4%, respectively. No grade 3 or 4 late toxicities were reported. Pretreatment prostate specific antigen (P=0.001) and Gleason score (P=0.03) were signifcant in predicting biochemical failure on multivariate analysis.

Conclusion: There is a high probability of tumor control with DE IG-IMRT combined with androgen deprivation, and this is a technique with a low probability of signifcant late toxicity. Our long term results corroborate the safety and effcacy of treating with IG-IMRT to high doses and compares favorably with published series for the treatment of prostate cancer.

Purpose: Dose-escalated (DE) radiotherapy in the setting of localized prostate cancer has been shown to improve biochemical disease-free survival (bDFS) in several studies. In the same group of patients, androgen deprivation therapy (ADT) has been shown to confer a survival benefit when combined with radiotherapy doses of up to 70 Gy; however, there is currently little long-term data on patients who have received high-dose intensity-modulated radiotherapy (IMRT) with ADT. We report the long-term outcomes in a large cohort of patients treated with the combination of DE image-guided IMRT (IG-IMRT) and ADT.

Original languageEnglish
Pages (from-to)1519-1523
Number of pages5
JournalOncoTargets and Therapy
Volume7
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

    Fingerprint

Keywords

  • Biochemical disease-free survival
  • Dose-escalation
  • Image-guided radiotherapy
  • Treatment related toxicity

Cite this